Repligen Corporation (RGEN) Raised to B- at TheStreet
Repligen Corporation (NASDAQ:RGEN) was upgraded by stock analysts at TheStreet from a “c+” rating to a “b-” rating in a research note issued to investors on Friday.
RGEN has been the subject of a number of other reports. BidaskClub cut shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. First Analysis reissued an “equal weight” rating and set a $40.00 price objective on shares of Repligen Corporation in a research note on Friday, April 21st. Zacks Investment Research raised shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Saturday. Jefferies Group LLC reissued a “hold” rating and set a $40.00 price objective (up from $33.00) on shares of Repligen Corporation in a research note on Wednesday, June 28th. Finally, William Blair initiated coverage on shares of Repligen Corporation in a research note on Friday, July 21st. They set an “outperform” rating for the company. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. Repligen Corporation presently has a consensus rating of “Buy” and a consensus target price of $42.00.
Shares of Repligen Corporation (NASDAQ RGEN) traded down 1.27% on Friday, hitting $41.08. The stock had a trading volume of 108,050 shares. The stock has a market cap of $1.53 billion, a PE ratio of 80.39 and a beta of 1.30. Repligen Corporation has a one year low of $26.16 and a one year high of $46.81. The company’s 50 day moving average is $41.83 and its 200 day moving average is $36.83.
Repligen Corporation (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.05. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The business had revenue of $32.40 million during the quarter, compared to analysts’ expectations of $31.72 million. During the same period last year, the company posted $0.16 EPS. The company’s revenue was up 11.0% on a year-over-year basis. Equities research analysts predict that Repligen Corporation will post $0.59 EPS for the current fiscal year.
A number of hedge funds have recently made changes to their positions in RGEN. Benin Management CORP purchased a new stake in shares of Repligen Corporation during the second quarter worth about $207,000. Macquarie Group Ltd. raised its stake in shares of Repligen Corporation by 481.1% in the fourth quarter. Macquarie Group Ltd. now owns 319,668 shares of the biotechnology company’s stock worth $9,852,000 after buying an additional 264,659 shares during the period. Karp Capital Management Corp purchased a new stake in shares of Repligen Corporation during the first quarter worth about $506,000. Invictus RG purchased a new stake in shares of Repligen Corporation during the first quarter worth about $233,000. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Repligen Corporation by 13.2% in the first quarter. BNP Paribas Arbitrage SA now owns 6,475 shares of the biotechnology company’s stock worth $228,000 after buying an additional 753 shares during the period. Hedge funds and other institutional investors own 99.49% of the company’s stock.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.